Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 13 h ago

Ovid Therapeutics Inc.: ADAR1 Capital Management, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

ADAR1 Capital Management, LLC filed an amended Schedule 13G with the SEC disclosing a change to its passive stake in Ovid Therapeutics Inc. (accession number 0001104659-26-128698). The filing updates the investment firm's previously reported beneficial ownership position in the biopharmaceutical company. Schedule 13G amendments are typically filed when a passive investor's ownership crosses the 5% threshold or shifts by more than 5% of the class, though the headline did not specify the exact stake or percentage change. The disclosure matters because it signals a shift in institutional ownership for the small-cap drug developer. Investors will watch for the full filing details to confirm ADAR1's current share count and whether further 13G or 13D activity follows.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Ovid Therapeutics Inc., ADAR1 Capital Management, LLC